During this phase, declining estrogen, changing insulin sensitivity, and redistribution of body composition create a distinct physiological context that warrants personalized medical evaluation
European Heart Journal - Cardiovascular Pharmacotherapy 10(4):296306 Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Effects are typically mild and dose-related, with subcutaneous administration sometimes causing local responses
Are we devolving to a 90s-era obsession with thinness
It may even cause scratching or scarring of the cornea
Compounded drugs go through a very different pathway at the FDA." Another misconception is that because a product lists the same active ingredients, it is equivalent to the name brand, she said